Functional status and health-related quality of life following Young and Burgess classified pelvic ring injuries
PLOS One · 09.04.2026 · 21 (4) · e0346671
DOI: 10.1371/journal.pone.0346671 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 09.04.2026. Verfasst von Camryn C Therrien und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Trauma Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Quality of Life, Pelvic Bones, Fractures, Bone, Functional Status. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
To determine recovery rates of patient-reported outcome measures (PROMs) in terms of functional status and health-related quality of life (HR-Qol) compared to the general population, as well as mortality rates and reintervention rates in patients with Young and Burgess (YB) classified pelvic ring injuries.
Methods
This cohort included patients with YB classified pelvic ring injuries in a level 1 trauma centre between 2007 and 2024. Dutch Short Musculoskeletal Function Assessment subscales were used to evaluate functional status, and the Dutch version of the EuroQol-5D 5L was used to assess HR-Qol. Outcomes were compared to normative data of the Dutch population. Patient-reported outcomes, mortality, and reintervention rates were reported for each YB classification. Full recovery was defined as reaching the lower level of the 95% confidence interval of the normative data in all outcome measures.
Results
PROMs were available for 346 (75%) of the eligible patients. The median follow-up time was 2.2 (IQR 3.6) years. The following rates of full recovery were observed: lateral compression (LC)1 = 41%, LC2 = 46%, LC3 = 11%, anterior posterior compression (APC)1 = 36%, APC2 = 33%, APC3 = 40%, vertical sheer (VS)=31% and combined mechanical injury (CM) =27%. The highest 30-day mortality rates were found in LC3 (19%), APC3 (16%), and VS (12%) injuries. LC3, APC3, VS, and CM injuries had the highest reintervention rates due to pain or discomfort.
Conclusion
Patients with LC1, LC2, APC1, APC2, and APC3 had comparable outcomes to the general population, while LC3, VS, and CM injuries had worse outcomes. LC3, APC3, and VS injuries had the highest mortality rates within 30 days of the initial trauma. LC3, APC3, VS, and CM had slightly higher levels of treatment revisions or removal of osteosynthesis material.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Trauma Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
- Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
ORCID-Profile: Camryn C Therrien, Anne M L Meesters, Inge H F Reininga
Zitieren
APA
Therrien, C. C., Uil, M., Ten Duis, K., Banierink, H., Meesters, A. M. L., Trouwborst, N. M., Hamminga, A. J., de Vries, J. P. M., IJpma, F. F. A., & Reininga, I. H. F. (2026). Functional status and health-related quality of life following Young and Burgess classified pelvic ring injuries. PLOS One, 21(4), e0346671. https://doi.org/10.1371/journal.pone.0346671
Vancouver
Therrien CC, Uil M, Ten Duis K, Banierink H, Meesters AML, Trouwborst NM, et al. Functional status and health-related quality of life following Young and Burgess classified pelvic ring injuries. PLOS One. 2026;21(4):e0346671. doi:10.1371/journal.pone.0346671
BibTeX
@article{Therrien2026,
author = {Therrien, Camryn C and Uil, Myrthe and Ten Duis, Kaj and Banierink, Hester and Meesters, Anne M L and Trouwborst, Nymke M and Hamminga, Anette J and de Vries, Jean-Paul P M and IJpma, Frank F A and Reininga, Inge H F},
title = {Functional status and health-related quality of life following Young and Burgess classified pelvic ring injuries},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {4},
pages = {e0346671},
doi = {10.1371/journal.pone.0346671}
}
EUVIMED